Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 60-4552 plus vardenafil versus vardenafil in PDE5 inhibitor-insufficient erectile dysfunction
NL-OMON34486Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in erectile dysfunction (ED) comparing BAY 60-4552 + vardenafil, Vardenafil alone and Placebo (3 arms). Primary endpoint: IIEF erectile function domain score. Started Nov 2010; status: active, not recruiting.
02
Drugs
nelociguatvardenafil
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NL-OMON34486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34486.